Altaris to Acquire Simulations Plus and Seek to Combine with Chemical Computing Group
June 16, 2026
New York, NY - Altaris, LLC (collectively with its managed funds, “Altaris”) today announced the signing of an agreement to acquire Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”) for $18.50 per share. Upon closing, Simulations Plus will become privately held and will be delisted from the Nasdaq Global Select Market. In connection with closing the transaction, Altaris anticipates Simulations Plus will be combined with Chemical Computing Group (“CCG”), an existing Altaris operating company, creating a broader biosimulation drug discovery and development platform. The transaction and subsequent combination is expected to close in the second half of 2026, subject to customary regulatory, shareholder, and other similar approvals and closing conditions.
The combination of Simulations Plus and CCG will bring together two well-established providers of scientific computational drug discovery and development tools. The companies serve many of the same customers and share similar cultural and operating philosophies. Together, the combined business will be better positioned to serve customers across the R&D lifecycle, with an enhanced ability to accelerate innovation across product offerings.
Simulations Plus is a global leader in model-informed and AI-accelerated drug development. Founded in 1996, Simulations Plus' software platforms, including GastroPlus, the Monolix Suite, ADMET Predictor, and the QSP/QST platform, are used by every top 20 pharmaceutical company and by CROs and regulators worldwide.
CCG is a leading provider of molecular modeling and drug discovery software. CCG's flagship product, the Molecular Operating Environment (MOE), is an industry-standard software platform for pre-clinical molecular design and has been adopted across the global biopharma industry for more than three decades.
Advisors
Truist Securities, Inc. and J.P. Morgan Securities LLC are acting as financial advisors to Altaris, and Bass, Berry & Sims PLC and Kirkland & Ellis LLP are acting as legal advisors to Altaris. Morgan Stanley & Co. LLC is acting as financial advisor to Simulations Plus, and Procopio, Cory, Hargreaves & Savitch LLP is acting as legal advisor to Simulations Plus.
About Altaris
Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare subsectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $9+ billion of equity capital. For more information, please visit www.altariscap.com.